Opinion|Videos|February 4, 2025
Treatment Sequencing in R/R CLL: Optimizing Strategies and Clinical Insights From ASH 2024 Real-World Data
Panelists discuss how treatment sequencing in chronic lymphocytic leukemia (CLL) should be personalized based on prior therapy responses and resistance patterns, with emerging real-world data from ASH 2024 informing decisions about re-treatment with drug classes and treatment holidays, while considering factors like durability of previous responses and the timing of molecular resistance.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What is your treatment sequencing approach? Is there an optimal treatment sequence?
- Please share your clinical treatment sequencing management and results from the ASH 2024 abstract P5114.
- Feel free to share any similarities or differences in practice in treatment sequencing.
- When do you consider re-treatment with the same class of drugs? When do you give patients treatment holidays?
Advertisement
Related to this article
Teclistamab plus talquetamab met the primary PFS end point and improved overall survival in relapsed/refractory multiple myeloma in MonumenTAL-6.
The FDA has granted priority review to a supplemental application for talazoparib plus enzalutamide in HRR-altered mCSPC.
Camizestrant plus a CDK4/6 inhibitor was approved in the European Union for ER-positive, HER2-negative advanced breast cancer with an emergent ESR1 mutation.
The FDA is reviewing data for daraxonrasib in previously treated pancreatic cancer under the Commissioner’s National Priority Voucher program.
Johannes Schetelig, MD, MSc, discusses phase 3 data for post-transplant cyclophosphamide vs ATLG as GVHD prophylaxis in hematologic malignancies.
Matthew Galsky, MD, discusses the FDA approval of perioperative pembrolizumab plus enfortumab vedotin in MIBC.
The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.
A 3-year, $225K award will focus on improving quality of life for patients living with long-term effects of cancer treatment.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
2
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
3
Dr Galsky on Systemic Therapy Advances in Muscle-Invasive Bladder Cancer
4
Dr Patel on the Unmet Need in EGFR+ Transformed Small Cell Lung Cancer
5